What is Hoth Therapeutics Operating Cash Flow per Share?
Hoth Therapeutics's operating cash flow per share for the
three
months ended in Dec. 2023 was $-0.71.
Hoth Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.54.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 41.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Hoth Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
HOTH'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -34.4 Med: 16.8 Max: 41.5
Current: 41.5
During the past 7 years, Hoth Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 41.50% per year. The lowest was -34.40% per year. And the median was 16.80% per year.
HOTH's 3-Year OCF Growth Rate is ranked better than 86.85% of 1240
companies
in the Biotechnology industry
Industry Median: 3.55
vs HOTH: 41.50
Hoth Therapeutics Operating Cash Flow per Share Historical Data
The historical data trend for Hoth Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Hoth Therapeutics Operating Cash Flow per Share Chart
Competitive Comparison of Hoth Therapeutics's Operating Cash Flow per Share
For the Biotechnology subindustry, Hoth Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hoth Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Hoth Therapeutics's Price-to-Operating-Cash-Flow falls into.
Hoth Therapeutics Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Hoth Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hoth Therapeutics Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Hoth Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Hoth Therapeutics (Hoth Therapeutics) Business Description
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HOTH has been successfully added to your 